Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $1.2 million.

  • Keros Therapeutics' Depreciation & Amortization (CF) rose 25.80% to $395,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 25.96%. This contributed to the annual value of $1.2 million for FY2024, which is 50.80% up from last year.
  • As of FY2024, Keros Therapeutics' Depreciation & Amortization (CF) stood at $1.2 million, which was up 50.80% from $815,000 recorded in FY2023.
  • Over the past 5 years, Keros Therapeutics' Depreciation & Amortization (CF) peaked at $1.2 million during FY2024, and registered a low of $278,000 during FY2020.
  • For the 3-year period, Keros Therapeutics' Depreciation & Amortization (CF) averaged around $906,000, with its median value being $815,000 (2023).
  • Data for Keros Therapeutics' Depreciation & Amortization (CF) shows a peak YoY spiked of 78.31% (in 2022) over the last 5 years.
  • Keros Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $278,000 in 2020, then skyrocketed by 35.97% to $378,000 in 2021, then skyrocketed by 78.31% to $674,000 in 2022, then rose by 20.92% to $815,000 in 2023, then spiked by 50.80% to $1.2 million in 2024.